A retrospective study of 35 patients with LM from EGFR-mutated NSCLC who exhibited disease progression after failure of standard-dose EGFR-TKIs showed that high-dose erlotinib (various dosages and regimens of high-dose erlotinib were used: 200 mg on alternate days, 300 mg on alternate days, 300 mg every 3 days, 450 mg every 3 days, and 600 mg every 4 days) showed a radiologic response in 30% of patients and symptomatic improvement in neurologic symptoms in 50% of patients. Here, EGFR is linked to non-small cell lung carcinoma.